ZURAZura Bio Limited

About Zura Bio Limited
Zura Bio (NASDAQ:ZURA) is a clinical-stage biotechnology company focused on developing innovative medicines for immune and inflammatory disorders. They currently have three assets in Phase 2 ready stage, targeting conditions like systemic sclerosis and other unmet medical needs. With a focus on novel therapies like tibulizumab (ZB-106) and torudokimab (ZB-880), Zura Bio aims to demonstrate their efficacy, safety, and dosing convenience. Despite a potentially overvalued stock, their strong balance sheet suggests they have the resources to advance their pipeline and potentially revolutionize treatment options for patients with these challenging conditions.
What is ZURA known for?
Snapshot
Public US
Ownership
2022
Year founded
15
Employees
California, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Zura Bio Limited
- Drug Pipeline: This is the core of Zura Bio's activity. It likely consists of several drug candidates in various stages of development, targeting specific immune and inflammatory disorders.
- Lead Candidates: Zura Bio might have 2-3 drug candidates in the most advanced stages (potentially Phase 2 ready), like tibulizumab (ZB-106) and torudokimab (ZB-880).
- Technology Platform: They might have a proprietary technology platform for developing novel immunotherapies or other treatments relevant to their focus area.
- Intellectual Property: Patents and other intellectual property would be crucial to protect their discoveries and potential commercialization of successful drugs.
- Research Partnerships: Collaborations with academic institutions or other companies might be part of their strategy to accelerate drug development.
- Investor Relations: Publicly traded companies like Zura Bio need to maintain investor relations activities to raise capital and keep investors informed about their progress.
equipe executiva do Zura Bio Limited
- Dr. Sandeep C. Kulkarni M.D.CEO & Director
- Dr. Someit Sidhu M.D.Founder & Director
- Ms. Kimberly Ann Davis J.D.COO, Chief Legal Officer & Corporate Secretary
- Dr. Kiran Nistala MBBS, Ph.D.Chief Medical Officer & Head of Development
- Mr. Eric HyllengrenChief Financial Officer
- Dr. Gary Whale Ph.D.Chief Technology Officer
- Ms. Theresa LowryChief Human Resources Officer